• To clarify the independent cell-cycle mechanisms through which the master regulators FOXM1 and CENPF contribute to acquisition of the lethal metastatic phenotype and therapeutic failure.
  • To investigate how the aberrant expression of chromatin modifiers in castration-resistant metastatic prostate cancer affects the AR cistrome and contributes to enzalutamide resistance.
  • To describe the spectrum of chromatin accessibility in advanced castration-resistant prostate cancer to complement the existing transcriptomic and genomic datasets.

Defining a mutational signature for endometrial cancer screening and early detection

Costas L., Palomero L., Benavente Y., Guardiola M., Frias-Gomez J., Pavón M., Climent M., Martinez J., Barahona M., Salinas M., Pineda M., Bianchi I., Reventós J., Capellà G., Diaz M., Vidal A., Piulats J., Ponce J., Brunet J., Bosch F., Matias-Guiu X., Alemany L., de Sanjosé S., Aytés Á.

2019

BRCA2 and Other DDR Genes in Prostate Cancer

Nombela P, Lozano R, Aytes A, Mateo J, Olmos D, Castro E

CANCERS. (ISSN/ISBN: 2072-6694). 11(3):

2019

New perspectives on screening and early detection of endometrial cancer

Costas L., Frias-Gomez J., Guardiola M., Benavente Y., Pineda M., Pavón M., Martínez J., Climent M., Barahona M., Canet J., Paytubi S., Salinas M., Palomero L., Bianchi I., Reventós J., Capellà G., Diaz M., Vidal A., Piulats J., Aytés Á., Ponce J., Brunet J., Bosch F., Matias-Guiu X., Alemany L., de Sanjosé S.

2019

Orthoxenografts of testicular germ cell tumors demonstrate genomic changes associated with cisplatin resistance and identify PDMP as a re-sensitizing agent.

Piulats JM, Vidal A, García-Rodríguez FJ, Muñoz C, Nadal M, Moutinho C, Martínez-Iniesta M, Mora J, Figueras A, Guinó E, Padullés L, Aytés À, Molleví DG, Puertas S, Martínez-Fernández C, Castillo W, Juliachs M, Moreno V, Muñoz P, Stefanovic M, Pujana MA, Condom E, Esteller M, Germà JR, Capella G, Farré L, Morales A, Viñals F, García-Del-Muro X, Cerón J, Villanueva A

CLINICAL CANCER RESEARCH (ISSN/ISBN: 10780432)

2018

NSD2 is a conserved driver of metastatic prostate cancer progression

Aytes A, Giacobbe A, Mitrofanova A, Ruggero K, Cyrta J, Arriaga J, Palomero L, Farran-Matas S, Rubin MA, Shen MM, Califano A, Abate-Shen C

NATURE COMMUNICATIONS. (ISSN/ISBN: 20411723). 9(1): 5201-5201

2018

Epigenetic Regulation in Prostate Cancer Progression.

Ruggero K, Farran-Matas S, Martinez-Tebar A, Aytes A

CURR MOL BIOL REP (ISSN/ISBN: 21986428). 4 (2) : 101-115

2018

A systems biology approach to predict drug response for human prostate cancer based on in vivo preclinical analyses of mouse models.

Aytes Meneses, Alvaro

CELL REPORTS (ISSN/ISBN: 22111247). 12 : 2060-2071

2015

DNA-PK mediated transcriptional regulation drives tumor progression and metastasis.

Aytes Meneses, Alvaro

CANCER CELL (ISSN/ISBN: 15356108). 28 : 97-113

2015

Cross-Species Regulatory Network Analysis Identifies a Synergistic Interaction between FOXM1 and CENPF that Drives Prostate Cancer Malignancy

Aytes, Alvaro; Mitrofanova, Antonina; Lefebvre, Celine; Alvarez, Mariano J.; Castillo-Martin, Mireia; Zheng, Tian; Eastham, James A.; Gopalan, Anuradha; Pienta, Kenneth J.; Shen, Michael M.; Califano, Andrea; Abate-Shen, Cory;

CANCER CELL (ISSN/ISBN: 15356108). 25 (5) : 638-651

2014

ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer

Aytes, Alvaro; Mitrofanova, Antonina; Kinkade, Carolyn Waugh; Lefebvre, Celine; Lei, Ming; Phelan, Vanessa; LeKaye, H. Carl; Koutcher, Jason A.; Cardiff, Robert D.; Califano, Andrea; Shen, Michael M.; Abate-Shen, Cory;

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (ISSN/ISBN: 00278424). 110 (37) : E3506-E3515

2013

See full list

Mechanisms ant therapeutic targeting of NSD2 in advanced prostate cancer

Aytes Meneses, Alvaro (Investigador principal (IP))

Entitat finançadora:
  • DEPARTMENT OF THE US ARMY

2018-09-30 - 2021-09-29

Diferenciació i Resistència Terapèutica del càncer (DiRT)

Aytes Meneses, Alvaro (Investigador principal (IP))

Entitat finançadora:
  • AGAUR-GENERAL.CATALUNYA

2018-01-01 - 2020-12-31

Mecanismos epigenéticos de resistencia a la castración en cancer de próstata: oportunidades terapéuticas en combinación con antagonistas del receptor de andrógenos.

Aytes Meneses, Alvaro (Investigador principal (IP))

Ref.: PI16/01070

Entitat finançadora:
  • FIS-INSTITUTO DE SALUD CARLOS III

2017-01-01 - 2019-12-31

PIE16/00049

Aytes Meneses, Alvaro (Investigador principal (IP))

Ref.: PIE16/00049

Entitat finançadora:
  • FIS-INSTITUTO DE SALUD CARLOS III

2017-01-01 - 2019-12-31

Mecanismos epigenéticos de resistencia a la castración en cancer de próstata: oportunidades terapéuticas en combinación con antagonistas del receptor de andrógenos

Aytes Meneses, Alvaro (Investigador principal (IP))

Ref.: IN[16]_BBM_TRA_0364AyudasFBBVAInvestigadoresyCreadoresCulturales

Entitat finançadora:
  • FUNDACIÓN BBVA

2016-10-01 - 2018-03-31

CONTRATOS MIGUEL SERVET TIPO I (CONTRATO)

Aytes Meneses, Alvaro (Investigador principal (IP))

Ref.: MS15/00090

Entitat finançadora:
  • FIS-INSTITUTO DE SALUD CARLOS III

2016-01-29 - 2021-01-28

Identification of molecular drivers of metastatic prostate cancer: the role of FOXM1 and CENPF in the deregulation of the epigenetic control of gene expression. IP: Alvaro Aytes Agencia Financiadora: ISCIII

Aytes Meneses, Alvaro (Coordinador/a científico/a)

Ref.: CP15/00090

Entitat finançadora:
  • MIGUEL SERVET TIPO TIPO I
  • INSTITUTO DE SALUD CARLOS III

2016-01-29 - 2019-01-28

Investigating causal mechanisms and novel therapeutic targets in CRPC after AR blockade failure.

Aytes Meneses, Alvaro (Investigador principal (IP)); Condom Munda, Enric (Participante)

Entitat finançadora:
  • EAU RESEARCH FOUNDATION

2016-01-29 - 2019-01-28

Identification of molecular drivers of metastatic prostate cancer: the role of FOXM1 and CENPF in the deregulation of the epigenetic control of gene expression.

Aytes Meneses, Alvaro (Investigador principal (IP))

Ref.: CP15/00090MiguelServetI(proyecto)

Entitat finançadora:
  • FIS-INSTITUTO DE SALUD CARLOS III

2016-01-01 - 2018-12-31

Investigating causal mechanisms and novel therapeutic targets in CRPC after AR blockade failure

Vidal Bel, August (Participante); Aytes Meneses, Alvaro (Coordinador del proyecto total, red o consorcio)

Ref.: EAURF/407003/XH

Entitat finançadora:
  • EUROPEAN ASSOCIATION OF UROLOGY RESEARCH FOUNDATION - CAREER TRACK

2016-01-01 - 2018-12-31

See full list

Methods and Compositions Relating to Phenotypic transition

Aytes Meneses, Alvaro (Inventores/autores/obtentores)

XenOPAT S.L

Aytes Meneses, Alvaro (Inventores/autores/obtentores)

See full list

Proyectos financiados por el Instituto de Salud Carlos III (ISCIII) y cofinanciados por el Fondo Europeo de Desarrollo Regional (FEDER):

 

Identification of molecular drivers of metastatic prostate cancer: the role of FOXM1 and CENPF in the deregulation of the epigenetic control of gene expression

CP15/00090. 01/2016-12/2018. 121.500 €. IP: Álvaro Aytés Meneses.

MS15/00090. 01/2016-01/2021. 202.500 €. IP: Álvaro Aytés Meneses.

Estudio del papel de la activación de FOXM1 y CENPF en la malignización del cáncer de próstata y si esta está mediada por mecanismos epigenéticos.